- 1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES
-
The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.
- -
-
Paragraph 0230; 0232
(2020/08/30)
-
- Bis(het)aryl-1,2,3-triazole quinuclidines as α7 nicotinic acetylcholine receptor ligands: Synthesis, structure affinity relationships, agonism activity, [18F]-radiolabeling and PET study in rats
-
In this paper we describe the design and synthesis of bis(Het)Aryl-1,2,3-triazole quinuclidine α7R ligands using an efficient three-step sequence including a Suzuki-Miyaura cross coupling reaction with commercially available and home-made boron derivatives. The exploration of SAR required the preparation of uncommon boron derivatives. Forty final drugs were tested for their ability to bind the target and nine of them exhibited Ki values below nanomolar concentrations. The best scores were always obtained when the 5-phenyl-2-thiophenyl core was attached to the triazole. The selectivity of these compounds towards the nicotinic α4β2 and serotoninergic 5HT3 receptors was assessed and their brain penetration was quantified by the preparation and in vivo evaluation of two [18F] radiolabelled derivatives. It can be expected from our results that some of these compounds will be suitable for further developments and will have effects on cognitive disorders.
- Ouach, Aziz,Vercouillie, Johnny,Bertrand, Emilie,Rodrigues, Nuno,Pin, Frederic,Serriere, Sophie,Boiaryna, Liliana,Chartier, Agnes,Percina, Nathalie,Tangpong, Pakorn,Gulhan, Zuhal,Mothes, Celine,Deloye, Jean-Bernard,Guilloteau, Denis,Page, Guylene,Suzenet, Franck,Buron, Frederic,Chalon, Sylvie,Routier, Sylvain
-
p. 449 - 469
(2019/07/03)
-
- [1,2,4]triazol[1,5-a]pyridine compound as well as preparation method and medical application thereof
-
The invention relates to a [1,2,4]triazol[1,5-a] pyridine compound as well as a preparation method and medical application thereof. Particularly, the invention relates to the compound shown in a general formula I, the preparation method of the compound, a
- -
-
Paragraph 0245-0246
(2018/03/24)
-
- Cell membrane permeable fluorescent perylene bisimide derivatives for cell lysosome imaging
-
We have developed acid activated fluorescent probes based on amphiphilic perylene bisimide with morpholine groups on the bay (Lyso-APBI). Incorporating one morpholine group, Lyso-APBI-1 showed an acid activated fluorescence increase of 70-fold upon pH values lowering from 8.0 to 4.0. Lyso-APBI-2, with two morpholine groups on the bay of PBI, had a red-shifted emission and a 190-fold fluorescence enhancement within same pH variation range. These Lyso-APBI probes have excellent membrane permeability, low cytotoxicity, and can rapidly accumulate and specifically activate in cell lysosomes. The double morpholine moieties make Lyso-APBI probes have higher acid activation ratio and better cell lysosome specificity. Moreover, long-time cell imaging proved the relatively high photostability of Lyso-APBI probes in a harsh physiological environment.
- Zhang, Shuchen,Duan, Wenfeng,Xi, Yanan,Yang, Tao,Gao, Baoxiang
-
p. 83864 - 83869
(2016/11/09)
-
- Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor
-
The phosphoinositide 3-kinase (PI3K) family is one of the most frequently activated enzymes in a wide range of human cancers; thus, inhibition of PI3K represents a promising strategy for cancer therapy. Herein, a series of benzylamine substituted arylsulfonamides were designed and synthesized as dual PI3K/mTOR inhibitors using a strategy integrating focused library design and virtual screening, resulting in the discovery of 13b (NSC765844). The compound 13b exhibits highly potent enzyme inhibition with IC50s of 1.3, 1.8, 1.5, 3.8 and 3.8?nM for PI3Kα, β, γ, δ, and mTOR, respectively. 13b was further evaluated in NCI by an in?vitro cytotoxic screening program. Broad-spectrum antitumor activities with mean GI50value of 18.6?nM against approximately 60 human tumor cell lines were found. 13b displayed favorable physicochemical properties and superior pharmacokinetic profiles for animal studies. It significantly inhibited tumor growth when administered orally in an A549 non-small-cell lung carcinoma xenograft and BEL7404 human hepatocellular carcinoma xenograft models. On the basis of its excellent in?vivo efficacy and superior pharmacokinetic profiles, 13b has been selected for further preclinical investigation as a promising anticancer drug candidate.
- Han, Jinsong,Chen, Ying,Yang, Chao,Liu, Ting,Wang, Mingping,Xu, Haojie,Zhang, Ling,Zheng, Canhui,Song, Yunlong,Zhu, Ju
-
p. 684 - 701
(2016/07/21)
-
- Anti-Malarial Agents
-
The present invention relates to a novel class of quinolone-4-carboxamide Pf3D7 inhibitors of general formula (I) (Formula (I)) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and in the treatment of malaria in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.
- -
-
Paragraph 0237-0241
(2015/02/25)
-
- ANTI-MALARIAL AGENTS
-
The present invention relates to a novel class of quinolone-4-carboxamide Pf3D7 inhibitors of general formula (I) (Formula (I)) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and in the treatment of malaria in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.
- -
-
Page/Page column 18; 39; 40
(2013/11/05)
-
- Kinase scaffold repurposing for neglected disease drug discovery: Discovery of an efficacious, lapatanib-derived lead compound for trypanosomiasis
-
Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei. Because drugs in use against HAT are toxic and require intravenous dosing, new drugs are needed. Initiating lead discovery campaigns b
- Patel, Gautam,Karver, Caitlin E.,Behera, Ranjan,Guyett, Paul J.,Sullenberger, Catherine,Edwards, Peter,Roncal, Norma E.,Mensa-Wilmot, Kojo,Pollastri, Michael P.
-
supporting information
p. 3820 - 3832
(2013/06/27)
-
- Synthesis of amines with pendant boronic esters by borrowing hydrogen catalysis
-
Amine alkylation reactions of alcohols have been performed in the presence of boronic ester groups to provide products which are known to have use as molecular sensors. The boronic ester moiety could be present in either the alcohol or amine starting mate
- Ma, Winson M. J.,James, Tony D.,Williams, Jonathan M. J.
-
p. 4850 - 4853
(2013/10/08)
-
- Microwave-mediated synthesis of an arylboronate library
-
A series of arylboronates has been synthesized from the reaction of 2-(2-, (3-, or (4-(bromomethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 1{1-3} respectively with a range of N-, S-, and O-nucleophiles, using microwave-mediated chemistry. For the synthesis of N- and S-substituted boronates, a supported base, PS-NMM, was employed, and many reactions were complete within 15 min. With O-nucleophiles, a mixture of tetrabutylammonium bromide, potassium carbonate, and sodium hydroxide was employed. The resulting aminomethyl, mercaptomethyl, or alkoxy-/phenoxymethyl-arylboronates were subjected to microwave-mediated Suzuki Miyaura coupling reactions to afford a range of biaryls in moderate to good yields. The X-ray structures of five boronates were determined.
- Spencer, John,Baltus, Christine B.,Patel, Hiren,Press, Neil J.,Callear, Samantha K.,Male, Louise,Coles, Simon J.
-
experimental part
p. 24 - 31
(2011/04/15)
-
- Discovery of a novel class of triazolones as Checkpoint Kinase inhibitors - Hit to lead exploration
-
Checkpoint Kinase-1 (Chk1, CHK1, CHEK1) is a Ser/Thr protein kinase that mediates cellular responses to DNA-damage. A novel class of Chk1 inhibitors, triazoloquinolones/triazolones (TZ's) was identified by high throughput screening. The optimization of th
- Oza, Vibha,Ashwell, Susan,Brassil, Patrick,Breed, Jason,Deng, Chun,Ezhuthachan, Jay,Haye, Heather,Horn, Candice,Janetka, James,Lyne, Paul,Newcombe, Nicholas,Otterbien, Ludo,Pass, Martin,Read, Jon,Roswell, Sian,Su, Mei,Toader, Dorin,Yu, Dingwei,Yu, Yan,Valentine, Anna,Webborn, Peter,White, Ann,Zabludoff, Sonya,Zheng, Xiaolan
-
supporting information; experimental part
p. 5133 - 5138
(2010/10/19)
-
- 2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors
-
A series of novel benzoxazole derivatives has been designed and shown to exhibit attractive JAK2 inhibitory profiles in biochemical and cellular assays, capable of delivering compounds with favorable PK properties in rats. Synthesis and structure-activity relationship data are also provided.
- Gerspacher, Marc,Furet, Pascal,Pissot-Soldermann, Carole,Gaul, Christoph,Holzer, Philipp,Vangrevelinghe, Eric,Lang, Marc,Erdmann, Dirk,Radimerski, Thomas,Regnier, Catherine H.,Chene, Patrick,Pover, Alain De,Hofmann, Francesco,Baffert, Fabienne,Buhl, Thomas,Aichholz, Reiner,Blasco, Francesca,Endres, Ralf,Trappe, J?rg,Drueckes, Peter
-
scheme or table
p. 1724 - 1727
(2010/07/03)
-
- TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS
-
A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A ph
- -
-
Page/Page column 143-144
(2010/01/12)
-
- 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer
-
Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential chemotherapeutic agents for cancer. Here, we describe the structure-based design, synthesis, structure - activity relationships and pharmacokinetics of potent small-molecule inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold. Analogues from this series have high affinity for Hsp90, as measured in a fluorescence polarization (FP) competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72. Compound 40f (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay (IC50 = 21 nM) and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM. Compound 40f is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice. In a human colon cancer xenograft model, 40f inhibits tumor growth by ~50%.
- Brough, Paul A.,Aherne, Wynne,Barril, Xavier,Borgognoni, Jenifer,Boxall, Kathy,Cansfield, Julie E.,Cheung, Kwai-Ming J.,Collins, Ian,Davies, Nicholas G. M.,Drysdale, Martin J.,Dymock, Brian,Eccles, Suzanne A.,Finch, Harry,Fink, Alexandra,Hayes, Angela,Howes, Robert,Hubbard, Roderick E.,James, Karen,Jordan, Allan M.,Lockie, Andrea,Martins, Vanessa,Massey, Andrew,Matthews, Thomas P.,McDonald, Edward,Northfield, Christopher J.,Pearl, Laurence H.,Prodromou, Chrisostomos,Ray, Stuart,Raynaud, Florence I.,Roughley, Stephen D.,Sharp, Swee Y.,Surgenor, Allan,Walmsley, D. Lee,Webb, Paul,Wood, Mike,Workman, Paul,Wright, Lisa
-
p. 196 - 218
(2008/09/17)
-
- SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS
-
Compounds in accord with Formula (I): wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the treatment of diseases mentioned in the specification.
- -
-
Page/Page column 51
(2008/06/13)
-
- ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS
-
The present invention is directed to compounds of formula (I), wherein R1 is a ring and n is a number from 1 to 8. The invention also relates to use of the compounds in therapy as metabotropic glutamate receptor modulators, particularly in neurological and psychiatric disorders.
- -
-
Page/Page column 108
(2008/06/13)
-
- Substituted 4-anilino-7-phenyl-3-quinolinecarbonitriles as Src kinase inhibitors
-
A series of substituted 4-anilino-7-phenyl-3-quinolinecarbonitriles has been prepared as Src kinase inhibitors. Optimal activity is observed with compounds that have basic amines attached via the para position of the 7-phenyl ring, and a hydrogen atom at the C-6 position. The best compounds are low nanomolar inhibitors of Src kinase, and have potent activity against Src-transformed fibroblast cells.
- Berger, Dan,Dutia, Minu,Powell, Dennis,Wissner, Allan,DeMorin, Frenel,Raifeld, Yuri,Weber, Jennifer,Boschelli, Frank
-
p. 2989 - 2992
(2007/10/03)
-
- 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
-
This invention provides compounds of Formula (I), having the structure where T, Z, X, A, R1, R2a, R2b, R2c, R3, R4, and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of osteoporosis and polycystic kidney disease.
- -
-
-